Trials / Active Not Recruiting
Active Not RecruitingNCT05192486
A Study of GNC-038, a Tetra-specific Antibody, in Participants With R/R Diffuse Large B-cell Lymphoma (DLBCL)
An Open-Label, Multi-Center, Phase Ib/II Study to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristics of Tetra-specific Antibody GNC-038 in Participants With Recurrent or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
- Status
- Active Not Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
In this study, the safety and preliminary efficacy of GNC-038 in participants with recurrent or refractory Diffuse Large B-cell lymphoma (DLBCL) will be investigated to assess the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) or maximum administered dose (MAD) for MTD is not reached of GNC-038. The recommended dose for phase II (RP2D) clinical study will also be determined.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GNC-038 | Administration by intravenous infusion |
Timeline
- Start date
- 2022-08-10
- Primary completion
- 2025-12-01
- Completion
- 2025-12-01
- First posted
- 2022-01-14
- Last updated
- 2025-09-26
Locations
4 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05192486. Inclusion in this directory is not an endorsement.